EKEirini Keskilidou

Eirini Keskilidou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Eirini Keskilidou has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • Efthymia Protonotariou

    Department of Microbiology, AHEPA University Hospital, Thessaloniki, Greece

    3 shared publications
  • Lemonia Skoura

    Department of Microbiology, AHEPA University Hospital, Thessaloniki, Greece

    3 shared publications
  • Paraskevi Mantzana

    Department of Microbiology, AHEPA University Hospital, School of Medicine, Aristotle University of Thessaloniki, Greece

    3 shared publications
  • Adonis A. Protopapas

    First Propaedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki, Greece

    2 shared publications
  • Areti Kourti

    Laboratory of Biological Chemistry, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, GR-54124 Thessaloniki, Greece

    2 shared publications
  • Christiana Gogou

    First Medical Propedeutic Department of Internal Medicine, AHEPA University Hospital, Thessaloniki, Greece

    2 shared publications

Latest Publications

  • Open Access

    GDF-15: Can It Be Used as a Biomarker in Acute Cerebrovascular Incidents?

    by Areti Kourti, Eirini Keskilidou, Alexandra Skoura, Paraskevi Karalazou, Katerina Thisiadou, Kali Makedou

    Background/Objectives: Growth differentiation factor-15 (GDF-15) is a protein that belongs to the transforming growth factor beta superfamily and has been found elevated in cases of organ injury such as liver, kidney, heart, and lung, as well as cardiovascular diseases and cancer. Soluble urokinase plasminogen activator receptor (suPAR) is a protein which is expressed mainly on immune cells and endothelial and smooth muscle cells, and is a marker of severity and intensity of inflammation in acute and chronic diseases. The aim of the present study was to compare GDF-15 serum levels between patients with acute cerebrovascular incidents and healthy controls and to investigate the possible correlation of GDF-15 serum levels and inflammatory markers, such as serum C-reactive protein (CRP) and plasma suPAR, in the above-mentioned groups. Methods: This is a retrospective study. Thirty-one patients were included in the study, with a mean age ± SD of 67 ± 13 years, compared to 18 age-matched healthy controls. Results: In the patient group a statistically significant positive correlation of serum levels of GDF15 values with suPAR and CRP emerged (rs = 0.516, p = 0.003) and (rs = 0.409, p = 0.022), respectively, and no significant correlation was found in the group of controls (rs = 0.271, p = 0.277) and (rs = 0.423, p = 0.080), respectively. Conclusions: These findings support the role of inflammation as a key underlying mechanism in acute cerebrovascular injury and suggest that GDF-15 may serve as a valuable adjunct biomarker for assessing disease severity and inflammatory burden.

  • Open Access

    Comparative measurement of plasma soluble urokinase plasminogen activator receptor using a point-of-care device and a clinical analyzer in stroke patients

    by Areti Kourti, Eirini Keskilidou, Alexandra Skoura, Athanasia Samara, Paraskevi Thanou, Paraskevi Karalazou, Katerina Thisiadou, Kali Makedou

    Background: Soluble urokinase plasminogen activator receptor (suPAR) reflects immune activation and chronic inflammatory responses and has been proposed as a prognostic biomarker in several acute conditions. Objectives: This study aims to evaluate the clinical performance of two analytical methods for plasma suPAR determination in patients with stroke: a point-of-care (POC) lateral-flow assay and an automated particle-enriched turbidimetric immunoassay performed on a biochemistry analyzer. Methods: Plasma samples from 27 patients with stroke and 14 age-matched healthy controls were analyzed with both methods. suPAR concentrations were significantly higher in stroke patients compared with controls for both assays. Results: A statistically significant difference between POC and analyzer measurements was observed only within the stroke group (p=0.024), and a strong positive correlation between the two methods was identified (r = 0.745, p<0.001). Receiver operating characteristic analysis demonstrated higher sensitivity for the POC method (96%) compared with the analyzer (82%), while the specificity was identical (57%). Conclusion: These findings suggest that suPAR measurement using a rapid POC platform provides reliable results and may support early risk stratification in patients with stroke in emergency department settings.

  • Authors’ reply to letter “Community and hospital-acquired gram-negative bloodstream infections in non-ICU patients: Addressing key limitations”

    by Eirini Keskilidou, Maria Kyziroglou, Georgios Meletis, Alexandra Tsankof, Erofili Papathanasiou, Christiana Gogou, Adonis Protopapas, Paraskevi Mantzana, Efthymia Protonotariou, Christos Savopoulos, et al.


  • Community and hospital-acquired gram-negative bloodstream infections in non-ICU patients

    by Eirini Keskilidou, Maria Kyziroglou, Georgios Meletis, Alexandra Tsankof, Erofili Papathanasiou, Christiana Gogou, Adonis Protopapas, Paraskevi Mantzana, Efthymia Protonotariou, Christos Savopoulos, et al.


  • Evaluation of the filmarray blood culture identification panel on diagnosis of bacteremias in an MDRO-endemic hospital environment

    by Eirini Keskilidou, Georgios Meletis, Olga Vasilaki, Georgia Kagkalou, Paraskevi Mantzana, Melania Kachrimanidou, Efthymia Protonotariou, Lemonia Skoura


  • Open Access

    In Vitro Synergistic Activity of Antimicrobial Combinations against Carbapenem- and Colistin-Resistant Acinetobacter baumannii and Klebsiella pneumoniae

    by Paraskevi Mantzana, Efthymia Protonotariou, Angeliki Kassomenaki, Georgios Meletis, Areti Tychala, Eirini Keskilidou, Maria Arhonti, Charikleia Katsanou, Aikaterini Daviti, Olga Vasilaki, et al.

    Polymyxins are commonly used as the last resort for the treatment of MDR Acinetobacter baumannii and Klebsiella pneumoniae nosocomial infections; however, apart from the already known toxicity issues, resistance to these agents is emerging. In the present study, we assessed the in vitro synergistic activity of antimicrobial combinations against carbapenem-resistant and colistin-resistant A. baumannii and K. pneumoniae in an effort to provide more options for their treatment. Two hundred A. baumannii and one hundred and six K. pneumoniae single clinical isolates with resistance to carbapenems and colistin, recovered between 1 January 2021 and 31 July 2022,were included. A. baumannii were tested by the MIC test strip fixed-ratio method for combinations of colistin with either meropenem or rifampicin or daptomycin. K. pneumoniae were tested for the combinations of colistin with meropenem and ceftazidime/avibactam with aztreonam. Synergy was observed at: 98.99% for colistin and meropenem against A. baumannii; 91.52% for colistin and rifampicin; and 100% for colistin and daptomycin. Synergy was also observed at: 73.56% for colistin and meropenem against K. pneumoniae and; and 93% for ceftazidime/avibactam with aztreonam. The tested antimicrobial combinations presented high synergy rates, rendering them valuable options against A. baumannii and K. pneumoniae infections.